The most effective therapeutic candidate for GRN correction demonstrated its effectiveness by extending to primary aortic valve cells derived from over 20 patients with sporadic aortic valve disease, and it successfully prevented aortic valve disease in a mouse model. This evidence concerns the gene GRN and aortic valve disorder.